Table 1 Characteristics of the overall population in the training and validation cohorts

Man(%)

85(65.4)

75(73.5)

0.183

Age(year)

48.0 (39.0-56.3)

52.5 (45.0–60.0)

0.003

Weight(/kg)

73.0 (63.0-83.5)

75.0 (65.8–84.0)

0.871

Course ≥ 6 months(%)

38(29.2)

27(26.5)

0.642

History of hypertension(%)

35(26.9)

30(29.4)

0.675

URBC(/Hp)

7.3(2.8–16.0)

11.7(5.0-24.3)

0.001

UWBC(/Hp)

2.4(1.2–5.4)

3.1(1.6–5.2)

0.251

UTP(g/24 h)

7.0(4.5–10.7)

6.1(3.5–10.5)

0.132

HGB(g/L)

140.5(128.0-149.3)

143.5(132.0-155.3)

0.101

ALB(g/L)

23.2(19.9–27.9)

26.0(21.3–30.4)

0.007

BUN(mmol/L)

4.6(3.7–5.4)

5.3(4.0-6.7)

0.001

Scr(μmol/L)

66.7(54.5–78.8)

72.9(63.7–84.1)

0.027

UA(μmol/L)

360.0(300.5-420.5)

367.6(295.8-451.1)

0.541

CysC(mg/L)

1.1(0.94–1.3)

1.1(0.9–1.4)

0.409

eGFR(mL/min/1.73m²)

95.9(80.2-109.6)

100.2(90.6-108.6)

0.164

TG(mmol/L)

2.2(1.6–3.7)

2.4(1.6–3.8)

0.568

TCHO(mmol/L)

7.4(6.1–8.9)

8.2(6.3–10.2)

0.012

D-dimer(μg/L)

242.0(149.0-505.8)

240.0(150.0-542.0)

0.840

sPLA2R-Ab(RU/mL)

58.0(10.0-142.2)

59.4(27.8-121.2)

0.564

Pathologic stage(%)

0.882

Stage I

10(9.6)

7(6.9)

Stage II

73(70.2)

73(71.6)

Stage III

19(18.3)

21(20.6)

Stage IV

2(1.9)

1(1.0)

Treatment options(%)

RAAS inhibitors

82(63.8)

72(70.6)

0.229

CTX

51(39.2)

48(47.1)

0.632

CNI

37(28.5)

24(23.5)

0.397

CD20 monoclonal antibody

2(1.5)

1(0.1)

1.000

Other immunosuppressant

1(0.8)

0(0)

1.000

Remission(%)

CR

45(34.6)

25(24.5)

0.096

PR

44(33.8)

45(44.1)

0.110

Progression(%)

NR

41(31.5)

32(31.4)

0.978